Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia
Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Two doses of 80 million adipose-tissue derived mesenchymal stem cells
Inclusion Criteria:
1. Age ≥ 18
2. Clinical diagnosis of Pneumonia, severe or critical, caused by COVID-19 infection
3. Life expectancy > 48 hours.
4. Commitment to use a contraceptive method of proven efficacy in both men and women
during the duration of the clinical trial.
Exclusion Criteria:
1. Coinfection with other viruses or bacteria (HIV, tuberculosis, influenza virus,
adenovirus or other respiratory infections, active infection by HBV or C).
2. History of multiple allergies, including allergy to Penicillin or other Blactams.
3. Pregnant and lactating women.
4. Patients with malignant tumors or hemopathies or any state of immunosuppression
considered as severe.
5. Patients with autoimmune diseases.
6. Chronic heart failure with ejection fraction less than 30%.
7. Any other condition for which, in the opinion of the main investigator, the subject is
considered not to be in compliance with the study.
Hospital Universitario de Jerez de la Frontera
Jerez de la Frontera, Cádiz, Spain
Hospital Reina Sofía
Córdoba, Spain
Hospital Universitario Virgen de las Nieves
Granada, Spain
Hospital Universitario Virgen Macarena
Sevilla, Spain
Hospital Unversitario Virgen del Rocío
Sevilla, Spain
Hospital Nuestra Señora de Valme
Sevilla, Spain